Standard-of-care treatment of APL includes arsenic trioxide (ATO) for proteasomal degradation of PML-RARα as well as the endogenous RARα ligand all-trans retinoic acid (ATRA), that provokes a strong remission of the disease via two major molecular mechanisms [20]. This evidence concerns the gene PML and acute promyelocytic leukemia.